

UNITED STATES DISTRICT COURT  
DISTRICT OF MASSACHUSETTS

----- X	
OKLAHOMA FIREFIGHTERS PENSION	:
AND RETIREMENT SYSTEM,	:
	:
Plaintiff,	:
	:
	:
v.	:
	:
BIOGEN INC., MICHEL VOUNATSOS,	:
ALFRED SANDROCK, AND ALISHA	:
ALAIMO,	:
	:
	:
Defendants.	:
----- X	

Civil Action:  
No. 22-10200-WGY

**LEAVE TO FILE  
GRANTED JULY 25, 2022**

**CONSOLIDATED MEMORANDUM  
OF LAW IN SUPPORT OF DEFENDANTS'  
MOTION TO DISMISS THE AMENDED COMPLAINT**

James R. Carroll  
Michael S. Hines  
Yaw A. Anim  
SKADDEN, ARPS, SLATE,  
MEAGHER & FLOM LLP  
500 Boylston Street  
Boston, Massachusetts 02116  
(617) 573-4800

*Counsel for Defendants  
Biogen Inc., Michel Vounatsos,  
Alfred Sandrock, and Alisha Alaimo*

Dated: July 27, 2022

## TABLE OF CONTENTS

PRELIMINARY STATEMENT .....	1
BACKGROUND .....	3
A.    Biogen And The FDA Evaluate The ADUHELM Phase 3 Clinical Trial Data .....	3
B.    After Examining The Clinical Trial Data The FDA Approves ADUHELM For The Treatment Of Alzheimer’s Disease .....	4
C.    Biogen Evaluates Healthcare Sites To Determine Their Capability, Infrastructure, Education And Willingness To Treat A Patient With A Potential New Alzheimer’s Therapy .....	5
D.    ADUHELM’s Commercial Launch .....	6
E.    Plaintiff’s Allegations .....	7
ARGUMENT .....	8
I.    THE COMPLAINT SHOULD BE DISMISSED IN ITS ENTIRETY BECAUSE IT DOES NOT ADEQUATELY ALLEGE THAT ANY STATEMENT WAS FALSE OR MISLEADING .....	8
A.    Statements Regarding The Number Of Healthcare Sites Ready To Implement ADUHELM .....	9
B.    Statements Regarding Diagnosing Patients With Alzheimer’s Disease .....	10
C.    Statements Regarding Medicare Coverage .....	11
D.    Statements Regarding Third-Party Payors’ “Approval” Of ADUHELM’s Pricing .....	13
E.    Statements Regarding Agreement With The Veteran’s Health Administration .....	13
F.    Statement In Dr. Sandroock’s Open Letter To The Alzheimer’s Disease Community .....	14

II.	THE COMPLAINT SHOULD BE DISMISSED IN ITS ENTIRETY FOR THE INDEPENDENT REASON THAT IT DOES NOT ALLEGE SPECIFIC FACTS SUPPORTING A “STRONG INFERENCE” OF SCIENTER.....	16
A.	The Complaint Fails To Allege A Strong Inference Of Scienter With Respect To Statements Concerning (i) Healthcare Site Readiness, (ii) Diagnosing Patients With Alzheimer’s Disease, (iii) Third-Party Payor Discussions, And (iv) An Agreement With The VA .....	18
1.	Dismissal Is Warranted Because The Former Employees Were Not Senior Management, And Are Not Alleged To Have Had Any Contact With Any Individual Defendant .....	18
2.	Former Employee Statements About Site Readiness Do Not Give Rise To A Strong Inference Of Scienter .....	21
3.	Former Employee Statements About Diagnosing Patients With Alzheimer’s Disease Do Not Give Rise To A Strong Inference Of Scienter .....	24
4.	Former Employee Statements About Third-Party Payors Do Not Give Rise To A Strong Inference Of Scienter .....	25
5.	Former Employee Statements About The VA’s Capacity To Cover And Administer ADUHELM Do Not Give Rise To A Strong Inference Of Scienter .....	26
B.	The Complaint Fails To Allege A Strong Inference Of Scienter With Respect To Statements About Medicare Coverage .....	27
C.	The Complaint Fails To Allege A Strong Inference Of Scienter With Respect To The Statement In Dr. Sandrock’s Open Letter To The Alzheimer’s Disease Community .....	27
D.	A Nonculpable Inference Under <i>Tellabs</i> Is More Compelling Than Scienter .....	28
III.	COUNT II SHOULD BE DISMISSED BECAUSE THERE IS NO PREDICATE EXCHANGE ACT VIOLATION .....	28
	CONCLUSION.....	29

..

**TABLE OF AUTHORITIES**

<b><u>CASES</u></b>	<b><u>Pages</u></b>
<i>ACA Financial Guaranty Corp. v. Advest, Inc.</i> , 512 F.3d 46 (1st Cir. 2008).....	8, 16, 28, 29
<i>Born v. Quad/Graphics, Inc.</i> , 521 F. Supp. 3d 469 (S.D.N.Y. 2021).....	13
<i>Chun v. Fluor Corp.</i> , No. 3:18-CV-01338-X, 2021 WL 1788626 (N.D. Tex. May 5, 2021).....	13
<i>Greebel v. FTP Software, Inc.</i> , 194 F.3d 185 (1st Cir. 1999).....	8
<i>In re Ariad Pharmaceuticals, Inc. Securities Litigation</i> , 842 F.3d 744 (1st Cir. 2016).....	17
<i>In re Boston Science Corp. Securities Litigation</i> , 686 F.3d 21 (1st Cir. 2012).....	17
<i>In re Biogen Inc. Securities Litigation</i> , 193 F. Supp. 3d 5 (D. Mass. 2016), <i>aff'd</i> , 857 F.3d 34 (1st Cir. 2017) .....	17
<i>In re Biogen Inc. Securities Litigation</i> , 857 F.3d 34 (1st Cir. 2017).....	9, 19, 21
<i>In re Garrett Motion Inc. Sec. Litig.</i> , No. 20 Civ. 7992 (JPC), 2022 WL 976269 (S.D.N.Y. Mar. 31, 2022) .....	7
<i>In re Genzyme Corp.</i> , No. 09-11267-GAO, 2012 WL 1076124 (D. Mass. Mar. 30, 2012), <i>aff'd</i> , 754 F.3d 31 (1st Cir. 2014) .....	28
<i>In re iRobot Corp. Securities Litigation</i> , No. 19-cv-12536, 2021 WL 950675 (D. Mass. Mar. 12, 2021) .....	20
<i>In re Karyopharm Therapeutics Inc., Securities Litigation</i> , 552 F. Supp. 3d 77 (D. Mass. 2021) .....	12, 13
<i>In re Peritus Software Services, Inc. Securities Litigation</i> , 52 F. Supp. 2d 211 (D. Mass. 1999) .....	24
<i>In re Zyprexa Products Liability Litigation</i> , 549 F. Supp. 2d 496 (E.D.N.Y. 2008) .....	12

...

<i>Local No. 8 IBEW Retirement Plan v. Vertex Pharmaceuticals Inc.</i> , 140 F. Supp. 3d 120 (D. Mass. 2015), <i>aff'd</i> , 838 F.3d 76 (1st Cir. 2016) .....	18, 29
<i>LSI Design &amp; Integration Corp. v. Tesaro, Inc.</i> , No. 18-cv-12352-LTS, 2019 WL 5967994 (D. Mass. Nov. 13, 2019).....	17
<i>Mahoney v. Foundation Medicine, Inc.</i> , 342 F. Supp. 3d 206 (D. Mass. 2018) .....	17
<i>Metzler Asset Management GmbH v. Kingsley</i> , 928 F.3d 151 (1st Cir. 2019).....	8, 22, 23, 25
<i>N.J. Carpenters Pension &amp; Annuity Funds v. Biogen IDEC Inc.</i> , 537 F.3d 35 (1st Cir. 2008).....	18
<i>Shaw v. Digital Equipment Corp.</i> , 82 F.3d 1194 (1st Cir. 1996).....	8
<i>Special Situations Fund III QP, L.P. v. Deloitte Touche Tohmatsu CPA, Ltd.</i> , 96 F. Supp. 3d 325 (S.D.N.Y. 2015).....	22
<i>Tellabs, Inc. v. Makor Issues &amp; Rights, Ltd.</i> , 551 U.S. 308 (2007).....	3, 28
<i>Whitehead v. Inotek Pharmaceuticals Corp.</i> , No. 17-cv-10025-LTS, 2018 WL 4732774 (D. Mass. Jun. 27, 2018).....	17

## **STATUTES, RULES & REGULATIONS**

15 U.S.C. § 78a .....	1
15 U.S.C. § 78t.....	29
15 U.S.C. § 78u-4 .....	8, 17, 20
17 C.F.R. § 240.10b-5.....	1
Fed. R. Civ. P. 9(b) .....	8

## **MISCELLANEOUS**

<i>Merriam-Webster's Collegiate Dictionary</i> (11th ed. 2020). .....	12
---	----

# Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

## Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

## Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

## Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

## API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

## LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

## FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

## E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.